Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,200.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective increased by equities researchers at Barclays from $1,050.00 to $1,200.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 11.08% from the company’s […]
More Stories
What to Know About UAE Leaving OPEC
By Owen Evans The United Arab Emirates’ decision to leave the Organization of the Petroleum Exporting Countries (OPEC) next month...
FCC Orders Early Review of Disney’s ABC Station Licenses
By Jill McLaughlin The Federal Communications Commission (FCC) has ordered an early review of license renewals for Disney’s ABC television...
President Trump, First Lady Host King Charles, Queen Camilla for State Dinner
By Travis Gillmore WASHINGTON—First Lady Melania Trump organized a lavish state dinner co-hosted by her husband President Donald Trump in...
US Sanctions 35 Individuals, Entities to Dismantle Iran’s Shadow Banking
By Kimberly Hayek The U.S. Treasury Department on April 28 imposed sanctions on 35 individuals and entities accused of running...
Iran War Pushes Gulf Allies to Request Dollar Help—What to Know
By Andrew Moran Treasury Secretary Scott Bessent confirmed last week that several U.S. allies in the Gulf region and Asia...
DC Shooting Suspect Charged With Attempting to Assassinate Trump
By Stacy Robinson and Jackson Richman WASHINGTON—The Department of Justice has charged Cole Allen, the suspect in the White House...